277 related articles for article (PubMed ID: 25486600)
41. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
[TBL] [Abstract][Full Text] [Related]
42. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
Arslan C
World J Urol; 2017 Mar; 35(3):479-480. PubMed ID: 27417948
[No Abstract] [Full Text] [Related]
43. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
44. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.
Francini E; Petrioli R; Roviello G
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1135-40. PubMed ID: 25135334
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
46. [Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S
Urologe A; 2014 May; 53(5):710-4. PubMed ID: 24806804
[TBL] [Abstract][Full Text] [Related]
47. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):576-583. PubMed ID: 29275450
[TBL] [Abstract][Full Text] [Related]
48. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
[TBL] [Abstract][Full Text] [Related]
49. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
Papazoglou D; Wannesson L; Berthold D; Cathomas R; Gillessen S; Rothermundt C; Hasler L; Winterhalder R; Barth A; Mingrone W; Nussbaum CU; von Rohr L; von Burg P; Schmid M; Richner J; Baumann S; Kühne R; Stenner F; Rothschild SI
Clin Genitourin Cancer; 2017 Jun; 15(3):e315-e323. PubMed ID: 27450512
[TBL] [Abstract][Full Text] [Related]
50. [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].
Berlin A; Fernández MI
Rev Med Chil; 2015 Feb; 143(2):223-36. PubMed ID: 25860365
[TBL] [Abstract][Full Text] [Related]
51. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
52. [Monitoring of treatment for metastatic castration-resistant prostate cancer].
Hinz S
Aktuelle Urol; 2017 May; 48(3):225-229. PubMed ID: 28614883
[TBL] [Abstract][Full Text] [Related]
53. Prostate cancer in 2014: The year chemotherapy finally gets some respect!
Saad F
Nat Rev Urol; 2015 Feb; 12(2):71-2. PubMed ID: 25600097
[No Abstract] [Full Text] [Related]
54. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Lu K
Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
[No Abstract] [Full Text] [Related]
55. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
56. Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison.
Chopra A; Georgieva M; Lopes G; Yeo CM; Haaland B
Prostate; 2017 May; 77(6):639-646. PubMed ID: 28101887
[TBL] [Abstract][Full Text] [Related]
57. Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Shao N; Zhu Y; Ye DW
Eur Urol Focus; 2019 Sep; 5(5):745-747. PubMed ID: 30797739
[TBL] [Abstract][Full Text] [Related]
58. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
59. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Izumi K; Mizokami A; Namiki M; Inoue S; Tanaka N; Yoshio Y; Ishibashi K; Kamiyama M; Kawai N; Enokida H; Shima T; Takahara S
BMC Cancer; 2017 Oct; 17(1):677. PubMed ID: 29017493
[TBL] [Abstract][Full Text] [Related]
60. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Bahl A
Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
